Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present ANGLE plc (OTC: ANPCY).

Full DD Report for ANPCY

Recent News from (OTC: ANPCY)

Angle PLC Announces Parsortix in Multiple Presentations at AACR
Angle's Parsortix System Showcased in Multiple Presentations at Leading Cancer Conference AACR 2018 Customers and Collaborators Publish more Successful Research with ANGLE's Parsortix Circulating Tumor Cell (CTC) Harvesting System in Four Poster Presentations Well Positioned to...
Source: ACCESSWIRE
Date: April, 19 2018 02:00
Angle PLC Announces Breakthrough Research with Parsortix
Breakthrough Research Demonstrates Parsortix Workflow for Culturing Circulating Tumor Cells for In-Vitro Drug Testing Unique Capabilities of ANGLE's Parsortix System Address a Key Aim of Precision Medicine to Test Drugs Outside the Patient to Determine Which Drugs will Benefit the Pa...
Source: ACCESSWIRE
Date: April, 19 2018 02:00
ANGLE (ANPCY) Presents At Proactive Investors One2One Investor Forum - Slideshow
The following slide deck was published by ANGLE plc ADR in conjunction with this Read more ...
Source: SeekingAlpha
Date: April, 06 2018 13:16
Angle PLC announces First patient enrolled in FDA study
FIRST PATIENT ENROLLED IN CLINICAL STUDY TO SUPPORT FDA CLEARANCE OF THE PARSORTIX SYSTEM FDA clearance would provide worldwide differentiation for the Parsortix system in the multi-billion dollar liquid biopsy market GUILDFORD, SURREY / ACCESSWIRE / April 5, 2018 / ANGLE...
Source: ACCESSWIRE
Date: April, 05 2018 02:00
Angle PLC announces Research Update
Angle's Ovarian Cancer Risk Assessment Achieves The Highest Sensitivity And Specificity For Predicting Cancer Detailed results of 200 patient study presented at the world's leading gynecologic oncology conference GUILDFORD, SURREY / ACCESSWIRE / March 26, 2018 / ANGLE plc (AIM:A...
Source: ACCESSWIRE
Date: March, 26 2018 02:00
ANGLE plc: Research Grant From Abbott
Abbott PathVysion HER-2 DNA Probe Assay to Be Used in ANGLE FDA Study GUILDFORD, SURREY / ACCESSWIRE / February 6, 2018 / ANGLE plc (''the Company'') (AIM: AGL; OTCQX: ANPCY), a world-leading liquid biopsy company, is delighted to announce that it has signed an agreement with global he...
Source: ACCESSWIRE
Date: February, 06 2018 02:00
Interim Results
-Interim Results for the six months ended 31 October 2017 -OVARIAN CANCER CLINICAL STUDIES SUCCESSFULLY COMPLETED -ACQUISITION ADDS DOWNSTREAM ANALYSIS TO PARSORTIX CTC HARVESTING PROVIDING COMPLETE 'SAMPLE TO ANSWER' CAPABILITY -INSTITUTIONAL REVIEW BOARD APPROVALS RECEI...
Source: ACCESSWIRE
Date: January, 31 2018 02:00
Webinar:Using Parsortix To Test Drugs On Live CTCS
WEBINAR: USING THE PARSORTIX TM SYSTEM TO IDENTIFY DRUGS THAT MAY ARREST CANCER METASTASIS GUILDFORD, SURREY / ACCESSWIRE / January 16, 2018 / ANGLE plc ("the Company") (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, announces that Professor Stuart Martin from the Univer...
Source: ACCESSWIRE
Date: January, 16 2018 02:20
ANGLE plc: Notice of Results
GUILDFORD, SURREY--(Marketwired - Jan 10, 2018) - ANGLE plc ( AIM : AGL ) ( OTCQX : ANPCY ) ANGLE plc ("ANGLE" or "the Company") Notification of Interim Results and Webcast ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, will be releasing its interim res...
Source: Marketwired
Date: January, 10 2018 05:56
ANGLE plc: Prostate cancer ARV7 treatment biomarker
GUILDFORD, SURREY--(Marketwired - Jan 8, 2018) - ( AIM : AG ) ( OTCQX : ANPCY ) ANGLE plc ("the Company") RESEARCH DEMONSTRATES USE OF PARSORTIX ™ LIQUID BIOPSY TO DETECT ARV7 IN PROSTATE CANCER AS A TREATMENT SELECTION BIOMARKER Parsortix-based ARV7 test may provide ...
Source: Marketwired
Date: January, 08 2018 02:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-04-21N/A7.0396N/AN/A0
2018-04-20N/A7.0396N/AN/A0
2018-04-19N/A7.0396N/AN/A0
2018-04-18N/A7.0396N/AN/A0
2018-04-17N/A7.0396N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2017-11-06100100100.0000Short
2017-09-13100100100.0000Short
2017-09-077575100.0000Short
2017-07-07200200100.0000Short
2017-07-06175175100.0000Short

* Short Mode

Short Analysis provided by Squeeze Report.


About ANGLE plc (OTC: ANPCY)

Logo for ANGLE plc (OTC: ANPCY)

ANGLE is a world leading liquid biopsy company with pioneering products in cancer diagnostics and foetal health. ANGLEs lead product is the Parsortix cell separation system, which can capture very rare cells from blood. This includes circulating tumour cells CTCs in cancer patient blood even when there is less than one CTC in one billion healthy cells. The resulting liquid biopsy simple blood test enables the investigation of mutations in the patient s cancer for personalised cancer care. ANGLE has launched a product for the research market and has secured CE Mark regulatory approval for the clinical market in Europe. The FDA authorization is in process. ANGLE is also undertaking clinical studies, the first on of which is in Ovarian Cancer for a clinical application to triage women having surgery for an abnormal pelvic mass to identify those with ovarian cancer. patient clinical studies in both Europe and the US have reported positive headline data and the test is being optimized before moving to validation studies. ANGLE has announced the acquisition of certain assets of Axela Inc, a novel multiplex diagnostic tool for the analysis of DNA, RNA and proteins.

 

 

 

Current Management

  • Andrew Newland / CEO
    • For over twenty five years, Andrew has specialised in building technologybased businesses based on strong intellectual property and for the last fifteen years he has been Chairman or on the Board of several specialist medical technology companies. Andrew has an MA in Engineering Science from the University of Cambridge, and is a qualified Chartered Accountant. After working with the engineering conglomerate, TI plc, he worked for KPMG from to from to he was based in the US as a manager providing corporate finance and business advice to high technology firms in the area around Route , Boston, Massachusetts. From to he worked for KPMG in the UK with responsibility for establishing KPMG s UK and European High Technology Practices and High Technology Consulting Group. Andrew founded ANGLE in . Together with ANGLE s senior management team, Andrew has cofounded and led eleven technology companies in partnership with world class research organisations, both in the UK and the US. Andrew has been instrumental in developing and then delivering the business proposition for these companies, building management teams, raising finance and securing revenues.
  • Ian Griffiths / CFO
    • Ian Griffiths is the Finance Director of ANGLE plc. He has specialised in technology commercialisation for over twenty years and is an expert on the development and growth of new technology based businesses. Ian has a BSc in Mathematics with Management Applications from Brunel University and is qualified as a chartered accountant. For seven years he worked for KPMG, initially in accountancy, then in management consulting within KPMG s High Technology Consulting Group where he specialised in financial modelling, business planning, corporate finance, market development and strategy work. He joined ANGLE in . As well as leading the finance function at ANGLE plc, he has been closely involved with the development and delivery of the UK, US and Middle East Consulting and Management businesses and in developing new Ventures, both third party and ANGLE s own. Ian has been heavily involved in the startup phase and also the ongoing development of ANGLE s own ventures by working closely with management on business plans, financial and operational management, fund raising and commercial aspects, including both medical and physical sciences companies. He is currently leading the financial development of ANGLE s major medical diagnostic business Parsortix.
  • Garth Selvey / Chairman, Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
    • Garth Selvey has a BSc in Physics and Electronics Engineering from the University of Manchester and has spent thirty six years in the computer industry with technical, product, sales and marketing roles. He became Managing Director of TIS Applications Ltd in and a main board director of TIS Ltd prior to its acquisition by Misys in . He organised the management buyout of the social housing division of Misys and became Group Chief Executive of Comino Group plc when it floated on AIM in . Comino moved to a full listing in where he remained until its successful public sale to Civica plc in February . Garth joined ANGLE as a Nonexecutive Director in September .
  • Brian Howlett / Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
    • Brian Howlett has a wealth of international experience as a medtech leader which he is currently applying in a NonExecutive / Chairman capacity for surgical graft company Vascular Flow Technologies Ltd, skin cancer imaging company Michelson Diagnostics Ltd and medical device coating and surface modification company Accentus Medical Ltd, as well as ANGLE plc. Brian was formerly CEO of Lombard Medical Technologies PLC, an AIM listed company specialising in stents for abdominal aortic aneurysms from to . Corporate experience includes six years as UK Country Leader of Boston Scientific Ltd, between and , during which time major medical devices such as the TAXUS drug eluting stent were launched driving sales and profits to the point where the UK and Ireland subsidiary became one of the leading revenue contributors to the Corporation s European operations. Between and , Brian was Managing Director of the UK sales and manufacturing subsidiary of Cobe Laboratories Inc. In addition, Brian spent almost years in the pharmaceutical industry, gaining strong sales and marketing experience through a number of senior management positions in UK, Scandinavia and the Benelux markets within Fisons plc. Brian joined ANGLE as a Nonexecutive Director in January .
  • Andrew Newland / For over twenty five years, Andrew has specialised in building technologybased businesses based on strong intellectual property and for the last fifteen years he has been Chairman or on the Board of several specialist medical technology companies. Andrew has an MA in Engineering Science from the University of Cambridge, and is a qualified Chartered Accountant. After working with the engineering conglomerate, TI plc, he worked for KPMG from to from to he was based in the US as a manager providing corporate finance and business advice to high technology firms in the area around Route , Boston, Massachusetts. From to he worked for KPMG in the UK with responsibility for establishing KPMG s UK and European High Technology Practices and High Technology Consulting Group. Andrew founded ANGLE in . Together with ANGLE s senior management team, Andrew has cofounded and led eleven technology companies in partnership with world class research organisations, both in the UK and the US. Andrew has been instrumental in developing and then delivering the business proposition for these companies, building management teams, raising finance and securing revenues.

Current Share Structure

  • Market Cap: $51,715,538 - 03/14/2018
  • Authorized: 0 - 03/14/2018
  • Issue and Outstanding: 73,463,745 - 04/30/2017
  • Float: 67,058,283 - 01/03/2017

 


Recent Filings from (OTC: ANPCY)

Interim Financial Report - Interim Financial Report
Filing Type: Interim Financial Report - Interim Financial ReportFiling Source: OTC Markets
Filing Date: March, 06 2018
Annual Report - Annual Report and Accounts to 30 April 2017
Filing Type: Annual Report - Annual Report and Accounts to 30 April 2017Filing Source: OTC Markets
Filing Date: October, 11 2017
Interim Financial Report - ANGLE plc Interim Report for the 6 months ended 31Oct16
Filing Type: Interim Financial Report - ANGLE plc Interim Report for the 6 months ended 31Oct16Filing Source: OTC Markets
Filing Date: March, 01 2017
Annual Report - Annual Report
Filing Type: Annual Report - Annual ReportFiling Source: OTC Markets
Filing Date: October, 28 2016
Interim Financial Report - ANGLE plc Interim Results to 31Oct15
Filing Type: Interim Financial Report - ANGLE plc Interim Results to 31Oct15Filing Source: OTC Markets
Filing Date: March, 09 2016
Interim Financial Report - ANGLE US PRN Interim Results Highlights 31Oct15 28Jan16
Filing Type: Interim Financial Report - ANGLE US PRN Interim Results Highlights 31Oct15 28Jan16Filing Source: OTC Markets
Filing Date: January, 28 2016
Annual Report - Annual Report
Filing Type: Annual Report - Annual ReportFiling Source: OTC Markets
Filing Date: September, 08 2015

 

 


Daily Technical Chart for (OTC: ANPCY)

Daily Technical Chart for (OTC: ANPCY)


Stay tuned for daily updates and more on (OTC: ANPCY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ANPCY)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

Monsta Trader
@MonstaTrader

 

 


Disclaimer: Monsta Trader publishes reports providing information on selected companies. Monsta Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. Monsta Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ANPCY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Monsta Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. Monsta Trader does not own any shares of ANPCY and does not buy, sell, or trade any shares of ANPCY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2016 by Monsta Trader. All rights reserved. Our Full Disclaimer: http://monstatrader.com/disclaimer/

 

 

Release this Report to Investors

Via Email

Via Text

Important

If you would like to schedule the release please Contact Us and we will assist you otherwise we will release this report to investors 15 minutes after payment is received to allow the most current information to be updated before the report is sent. Interested in reaching more investors? Contact Us